Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of 8 weeks of once-daily (QD)
treatment with dexlansoprazole modified release (MR) 60 mg or 90 mg or lansoprazole 30 mg in
healing subjects with endoscopically proven erosive esophagitis.